Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Clinical trial NCT05256225 · RECRUITING

Trial details

NCT number: NCT05256225
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Endometrial Carcinoma Endometrial Clear Cell Adenocarcinoma Endometrial Dedifferentiated Carcinoma Endometrial Endometrioid Adenocarcinoma Endometrial Mixed Cell Adenocarcinoma Endometrial Serous Adenocarcinoma Endometrial Undifferentiated Carcinoma Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor

Start date: 2022-11-16
Primary completion: 2027-10-31
Enrollment: 360

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.